Spotlight on Reteplase in Thrombotic Occlusive Disorders

@article{Simpson2012SpotlightOR,
  title={Spotlight on Reteplase in Thrombotic Occlusive Disorders},
  author={D. Simpson and M. A. Siddiqui and L. Scott and D. Hilleman},
  journal={BioDrugs},
  year={2012},
  volume={21},
  pages={65-68}
}
  • D. Simpson, M. A. Siddiqui, +1 author D. Hilleman
  • Published 2012
  • Medicine
  • BioDrugs
  • Reteplase (Retavase®) is a plasminogen activator, mimicking endogenous tissue plasminogen activator (t-PA), a serine protease, converting plasminogen to plasmin and thereby precipitating thrombolysis. It is a third-generation recombinant form of t-PA that operates in the presence of fibrin (i.e. it is fibrin specific).Reteplase can be administered as a bolus dose (nonweight-based), rather than an infusion, which promotes rapid and safe administration. The ease of administration of this… CONTINUE READING
    14 Citations
    Clot penetration and retention by plasminogen activators promote fibrinolysis.
    • 9
    • Highly Influenced
    Efficacy evaluation of reteplase in a novel canine acute pulmonary thromboembolism model developed by minimally invasive surgery and digital subtraction angiography
    • 1
    • Highly Influenced
    • PDF
    Antithrombotic Drugs-Pharmacology and Perspectives.
    Role of thrombolysis in reperfusion therapy for management of AMI: Indian scenario.
    • 10
    • PDF
    Emerging paradigms in nanotechnology for imaging and treatment of cerebral ischemia.
    • 8
    Successful treatment of prosthetic pulmonary valve thrombosis with reteplase: a case report
    • PDF

    References

    SHOWING 1-10 OF 58 REFERENCES
    Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction.
    • 53
    • Highly Influential
    Current Clinical Use of Reteplase for Thrombolysis
    • 25
    Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial.
    • 56